Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation - Tang, Guo-Qing; Tang, Yalan; Dhamnaskar, Ketki; Hoarty, Michelle D.; Vyasamneni, Rohit; Vadysirisack, Douangsone D.; Ma, Zhong; Zhu, Nanqun; Wang, Jian-Guo; Bu, Charlie; Cong, Bestine; Palmer, Elizabeth; et al. (Frontiers in Immunology, 2023)